GP IIb/IIIa Meta-Analysis Would Not Provide Suitable Active Control - Cmte.

A meta-analysis of approved GP IIb/IIIa inhibitors would not provide the best comparator arm for active-control trials of new drugs in the class, FDA's Cardiovascular & Renal Drugs Advisory Committee concluded Oct. 14.